Cannabis in Adults with Cancer
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
Treatm...
...inical Communication and Educa...
...n 1.1Health systems and clinicians, in pa...
...on 1.2Given the high prevalence of cannabis and/or...
...ecommendation 1.3When adults with cance...
...er Treatment
...mmendation 2.1Clinicians should recommend against...
...mmendation 2.2Clinicians should re...
...ncer Treatment-related Toxicity, Symptoms...
...endation 3.1...
...and nabilone] (EB, , M, Weak)3499376...
...:1 THC:CBD extract] (EB, , L, Weak)3499376...
...on 3.2Outside of a clinical trial, clinic...
...3.3Evidence remains insufficient to recomm...
...an In-depth History of Cannabis and/or Cannabino...
.... Summary of Recommendations Pertaining to Use...
...General Safety AwarenessHaving trouble vie...
...re 1. Endocannabinoid...
...ves that cancer clinical trials are vital to...